FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011131024> ?p ?o ?g. }

• W2011131024 abstract "You have accessJournal of UrologyProstate Cancer: Detection and Screening III1 Apr 2015PD38-02 METASTATIC PROSTATE CANCER IN THE MODERN ERA OF PSA SCREENING Philip Fontenot, Avinash Nehra, Hadley Wyre, Moben Mirza, Jeffrey Holzbeierlein, J. Brantley Thrasher, Peter Van Veldhuizen, and Eugene Lee Philip FontenotPhilip Fontenot More articles by this author , Avinash NehraAvinash Nehra More articles by this author , Hadley WyreHadley Wyre More articles by this author , Moben MirzaMoben Mirza More articles by this author , Jeffrey HolzbeierleinJeffrey Holzbeierlein More articles by this author , J. Brantley ThrasherJ. Brantley Thrasher More articles by this author , Peter Van VeldhuizenPeter Van Veldhuizen More articles by this author , and Eugene LeeEugene Lee More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2423AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Prostate cancer continues to be the second leading cause of cancer death in American men. Studies evaluating the benefit of screening have been controversial and there has been no universal consensus. Our objective was to characterize the initial presentation and PSA screening in men who have metastasis and/or have died of disease in a contemporary cohort. METHODS After IRB approval, the medical records of 93 men diagnosed with metastatic prostate cancer or who died of disease between 2008 to 2014 were evaluated. First, we assessed the method of initial presentation and placed them into four groups. Groups 1 and 2 presented initially with presumed localized disease and were treated with surgery or radiation but recurred late (>1 year; Group 1) or early (<1 year; Group 2). Groups 3 and 4 were patients who presented with asymptomatic (Group 3) and symptomatic (Group 4) metastatic disease. For each group, we evaluated the trend of PSA screening. Patients who had their first PSA test prior to the age of 55 were considered to have undergone standard screening. RESULTS In our cohort, groups 1, 2, 3 and 4 had 22 (24%), 4 (4%), 35 (38%) and 32 (34%) patients, respectively. In Group 1, while 20/22 (91%) patients had a PSA prior to primary treatment, only 4 (18%) had undergone standard PSA screening with a first test before the age of 55. In Group 2, we had PSA data on 3 patients of which 0/3 (0%) received standard screening. In Group 3, 9/33 (28%) underwent standard screening prior to presentation with asymptomatic metastatic disease. In Group 4, 3/32 (9%) patients had undergone standard screening prior to presentation with symptomatic metastatic disease. CONCLUSIONS Despite widespread screening efforts during the timeframe of this analysis, the majority of patients with clinically relevant prostate cancer (metastasis and/or death from prostate cancer) presented with metastatic disease 67/93 (72%). Furthermore, in the entire cohort, only 19/90 (21%) patients had received standard PSA screening before the age of 55. This data underscores the notion that despite mass screening, patients who develop incurable disease are not failures of screening but never undergo appropriate testing in the first place. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e824-e825 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Philip Fontenot More articles by this author Avinash Nehra More articles by this author Hadley Wyre More articles by this author Moben Mirza More articles by this author Jeffrey Holzbeierlein More articles by this author J. Brantley Thrasher More articles by this author Peter Van Veldhuizen More articles by this author Eugene Lee More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2011131024 created "2016-06-24" @default.
• W2011131024 creator A5001225071 @default.
• W2011131024 creator A5007086736 @default.
• W2011131024 creator A5013381071 @default.
• W2011131024 creator A5051010668 @default.
• W2011131024 creator A5053587866 @default.
• W2011131024 creator A5077312194 @default.
• W2011131024 creator A5082420072 @default.
• W2011131024 creator A5090369191 @default.
• W2011131024 date "2015-04-01" @default.
• W2011131024 modified "2023-10-17" @default.
• W2011131024 title "PD38-02 METASTATIC PROSTATE CANCER IN THE MODERN ERA OF PSA SCREENING" @default.
• W2011131024 doi "https://doi.org/10.1016/j.juro.2015.02.2423" @default.
• W2011131024 hasPublicationYear "2015" @default.
• W2011131024 type Work @default.
• W2011131024 sameAs 2011131024 @default.
• W2011131024 citedByCount "0" @default.
• W2011131024 crossrefType "journal-article" @default.
• W2011131024 hasAuthorship W2011131024A5001225071 @default.
• W2011131024 hasAuthorship W2011131024A5007086736 @default.
• W2011131024 hasAuthorship W2011131024A5013381071 @default.
• W2011131024 hasAuthorship W2011131024A5051010668 @default.
• W2011131024 hasAuthorship W2011131024A5053587866 @default.
• W2011131024 hasAuthorship W2011131024A5077312194 @default.
• W2011131024 hasAuthorship W2011131024A5082420072 @default.
• W2011131024 hasAuthorship W2011131024A5090369191 @default.
• W2011131024 hasConcept C121608353 @default.
• W2011131024 hasConcept C126322002 @default.
• W2011131024 hasConcept C141071460 @default.
• W2011131024 hasConcept C2777601897 @default.
• W2011131024 hasConcept C2779013556 @default.
• W2011131024 hasConcept C2779134260 @default.
• W2011131024 hasConcept C2780192828 @default.
• W2011131024 hasConcept C61434518 @default.
• W2011131024 hasConcept C71924100 @default.
• W2011131024 hasConceptScore W2011131024C121608353 @default.
• W2011131024 hasConceptScore W2011131024C126322002 @default.
• W2011131024 hasConceptScore W2011131024C141071460 @default.
• W2011131024 hasConceptScore W2011131024C2777601897 @default.
• W2011131024 hasConceptScore W2011131024C2779013556 @default.
• W2011131024 hasConceptScore W2011131024C2779134260 @default.
• W2011131024 hasConceptScore W2011131024C2780192828 @default.
• W2011131024 hasConceptScore W2011131024C61434518 @default.
• W2011131024 hasConceptScore W2011131024C71924100 @default.
• W2011131024 hasIssue "4S" @default.
• W2011131024 hasLocation W20111310241 @default.
• W2011131024 hasOpenAccess W2011131024 @default.
• W2011131024 hasPrimaryLocation W20111310241 @default.
• W2011131024 hasRelatedWork W165735305 @default.
• W2011131024 hasRelatedWork W1899936169 @default.
• W2011131024 hasRelatedWork W2132373402 @default.
• W2011131024 hasRelatedWork W2147159125 @default.
• W2011131024 hasRelatedWork W2212921542 @default.
• W2011131024 hasRelatedWork W2404243088 @default.
• W2011131024 hasRelatedWork W2789349946 @default.
• W2011131024 hasRelatedWork W2937851053 @default.
• W2011131024 hasRelatedWork W4214799196 @default.
• W2011131024 hasRelatedWork W4214955067 @default.
• W2011131024 hasVolume "193" @default.
• W2011131024 isParatext "false" @default.
• W2011131024 isRetracted "false" @default.
• W2011131024 magId "2011131024" @default.
• W2011131024 workType "article" @default.